These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 23097067)

  • 41. Ferric carboxymaltose in patients with heart failure and iron deficiency.
    Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
    N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure.
    Lewis GD; Lachmann J; Camuso J; Lepore JJ; Shin J; Martinovic ME; Systrom DM; Bloch KD; Semigran MJ
    Circulation; 2007 Jan; 115(1):59-66. PubMed ID: 17179022
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Letter by Jamous regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".
    Jamous FG
    Circulation; 2012 Feb; 125(8):e407; author reply e409-10. PubMed ID: 22371449
    [No Abstract]   [Full Text] [Related]  

  • 44. Letter by Forfia and Borlaug regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".
    Forfia PR; Borlaug BA
    Circulation; 2012 Feb; 125(8):e408; author reply e409-10. PubMed ID: 22371450
    [No Abstract]   [Full Text] [Related]  

  • 45. Letter by Gordon et al regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".
    Gordon B; McDiarmid A; MacGowan G
    Circulation; 2012 Feb; 125(8):e406; author reply e409-10. PubMed ID: 22371448
    [No Abstract]   [Full Text] [Related]  

  • 46. Controlled study of myocardial recovery after interval training in heart failure: SMARTEX-HF--rationale and design.
    Støylen A; Conraads V; Halle M; Linke A; Prescott E; Ellingsen Ø
    Eur J Prev Cardiol; 2012 Aug; 19(4):813-21. PubMed ID: 21450567
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: a double-blind, placebo-controlled, randomized study.
    Safarinejad MR; Taghva A; Shekarchi B; Safarinejad Sh
    Int J Impot Res; 2010; 22(5):325-35. PubMed ID: 20861846
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sildenafil citrate therapy for pulmonary arterial hypertension.
    Galiè N; Ghofrani HA; Torbicki A; Barst RJ; Rubin LJ; Badesch D; Fleming T; Parpia T; Burgess G; Branzi A; Grimminger F; Kurzyna M; Simonneau G;
    N Engl J Med; 2005 Nov; 353(20):2148-57. PubMed ID: 16291984
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison and validation of three measures of quality of life in patients with pulmonary hypertension.
    Chua R; Keogh AM; Byth K; O'Loughlin A
    Intern Med J; 2006 Nov; 36(11):705-10. PubMed ID: 17040356
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relation of Longitudinal Changes in Quality of Life Assessments to Changes in Functional Capacity in Patients With Heart Failure With and Without Anemia.
    Cooper TJ; Anker SD; Comin-Colet J; Filippatos G; Lainscak M; Lüscher TF; Mori C; Johnson P; Ponikowski P; Dickstein K
    Am J Cardiol; 2016 May; 117(9):1482-7. PubMed ID: 27015889
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Response to a single dose of sildenafil in single-ventricle patients: an echocardiographic evaluation.
    Jackson KW; Butts RJ; Svenson AJ; McQuinn TC; Atz AM
    Pediatr Cardiol; 2013 Oct; 34(7):1739-42. PubMed ID: 22806713
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sildenafil and exercise capacity in heart failure.
    Guazzi M; Bandera F; Forfia P
    JAMA; 2013 Jul; 310(4):432. PubMed ID: 23917301
    [No Abstract]   [Full Text] [Related]  

  • 53. Sildenafil and exercise capacity in heart failure--in reply.
    Redfield MM; Borlaug BA
    JAMA; 2013 Jul; 310(4):432-3. PubMed ID: 23917302
    [No Abstract]   [Full Text] [Related]  

  • 54. A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design.
    Zile M; Gaasch W; Little W; Francis G; Tavazzi L; Cleland J; Davies M;
    J Card Fail; 2004 Jun; 10(3):193-9. PubMed ID: 15190528
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Particular challenges in the use of pulmonary vasodilating therapy for patients with pulmonary hypertension secondary to left heart disease. Letter regarding the article 'Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial'.
    Dandel M; Hetzer R
    Eur J Heart Fail; 2022 Oct; 24(10):1990. PubMed ID: 35853842
    [No Abstract]   [Full Text] [Related]  

  • 56. Variability in the clinical status of patients with advanced heart failure.
    Hauptman PJ; Masoudi FA; Weintraub WS; Pina I; Jones PG; Spertus JA;
    J Card Fail; 2004 Oct; 10(5):397-402. PubMed ID: 15470650
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rationale and design of the Study of Dietary Intervention Under 100 MMOL in Heart Failure (SODIUM-HF).
    Colin-Ramirez E; Ezekowitz JA;
    Am Heart J; 2018 Nov; 205():87-96. PubMed ID: 30205241
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV-INHIBITION study design.
    Amedro P; Gavotto A; Abassi H; Picot MC; Matecki S; Malekzadeh-Milani S; Levy M; Ladouceur M; Ovaert C; Aldebert P; Thambo JB; Fraisse A; Humbert M; Cohen S; Baruteau AE; Karsenty C; Bonnet D; Hascoet S;
    ESC Heart Fail; 2020 Apr; 7(2):747-756. PubMed ID: 32147955
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure : Design and rationale of the MONITOR HF multicentre randomised clinical trial.
    Brugts JJ; Veenis JF; Radhoe SP; Linssen GCM; van Gent M; Borleffs CJW; van Ramshorst J; van Pol P; Tukkie R; Spee RF; Emans ME; Kok W; van Halm V; Handoko L; Beeres SLMA; Post MC; Boersma E; Lenzen MJ; Manintveld OC; Koffijberg H; van Baal P; Versteegh M; Smilde TD; van Heerebeek L; Rienstra M; Mosterd A; Delnoy PPH; Asselbergs FW; Brunner-La Rocca HP; de Boer RA
    Neth Heart J; 2020 Jan; 28(1):16-26. PubMed ID: 31776915
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nitrate's effect on activity tolerance in heart failure with preserved ejection fraction trial: rationale and design.
    Zakeri R; Levine JA; Koepp GA; Borlaug BA; Chirinos JA; LeWinter M; VanBuren P; Dávila-Román VG; de Las Fuentes L; Khazanie P; Hernandez A; Anstrom K; Redfield MM
    Circ Heart Fail; 2015 Jan; 8(1):221-8. PubMed ID: 25605640
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.